載入...
Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAF(V600E) Mutation
BACKGROUND: Clinical benefit from cytotoxic chemotherapy for metastatic papillary thyroid carcinoma (PTC) is disappointing, and effective therapeutic approaches for these patients are urgently needed. Because kinase-activating mutations in the BRAF proto-oncogene commonly occur in advanced PTC, and...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Mary Ann Liebert, Inc.
2013
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3967415/ https://ncbi.nlm.nih.gov/pubmed/23489023 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2013.0057 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|